News

Alvotech has closed a licensing and settlement agreement with Regeneron and Bayer that clears all patent disputes worldwide over its biosimilar to Eylea. The deal gives Alvotech worldwide rights to manufacture and supply the product to global commercial partners—except for the United States, where a separate agreement had already been announced. Un...

Full article

OKYO’s previous phase 2 data showed statistically significant improvements in several endpoints for neuropathic corneal pain patients, reinforcing the potential of urcosimod. The confirmation of the primary endpoint and the alignment on key trial components position the company to advance its novel ocular‑disease–focused pipeline.

Full article

The meeting also validated OKYO Pharma’s Chemistry, Manufacturing and Controls (CMC) strategy and the ocular pain assessment survey (OPAS) used in the protocol. With these elements cleared, the company plans to commence a 120‑patient, multiple‑dose phase 2b/3 study during the first half of 2026.

Full article

BioNTech SE’s shares hovered at $118.00 on January 26, giving the company a trailing P/E of 166.87 and a forward P/E of 7.04. Management signals 2026 will be a transitional year, with a subdued revenue outlook but a potentially pivotal moment for the oncology franchise. The firm holds roughly $17 billion in cash, allowing it to pursue pipeline deve...

Full article

Segment‑level outlooks: the Healthcare unit is expected to achieve an 8.1 % YoY revenue gain, driven by its continued strong growth trend. The Applied Sterilization Technologies (AST) segment is projected to grow organically and benefit from rising bioprocessing demand. Life Sciences is anticipated to uphold the robust expansion seen in consumables...

Full article

Despite robust forward metrics, risks remain. Execution complexity and customer concentration could delay progress, while the firm’s zero‑carbon claims are disputed. Aggressive leverage threatens dilution, and the valuation already assumes a flawless rollout, leaving little room for cost overruns.

Full article

Strategic partnerships reinforce the company’s scale plans. TeraWulf signed an $8.7 billion, 10‑year lease with Fluidstack, and the two firms will jointly develop a 168‑MW HPC facility in Texas. These commitments position the firm to grow from 22.5 MW of energized HPC capacity to nearly 600 MW in the 2026‑2027 window, meeting the projected demand f...

Full article

The company’s pivot from pure‑play bitcoin mining to high‑performance computing (HPC) and AI data‑centre infrastructure has brought it to a key inflection point. As of Q3 2025, TeraWulf saw 84 % year‑over‑year growth and posted positive adjusted EBITDA, with a forward P/E of 29.76. Its forward revenue is anchored by $6.7 billion of contracted HPC b...

Full article

TeraWulf Inc. (NASDAQ: WULF) closed its Tuesday session at $15.31, up 11.02% from a $13.79 close on January 26. The rally was driven by heightened sector optimism after Nvidia’s $2 billion investment in CoreWeave, underscoring confidence in AI infrastructure.

Full article

The company carries a Zacks Rank of #4 (Sell), reflecting a perception of underperformance relative to the broader market, although recent earnings surprises and capital‑allocation plans provide a counter‑signal. The stock has gained approximately 8.4 % in value since the start of the year, outpacing the S&P 500’s 1.9 % gain.

Full article